Navigation Links
New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
Date:10/16/2007

NORTH BRUNSWICK, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Researchers testing a vaccine based on the live bacteria Listeria, in women with advanced cervical cancer found it to be safe. The Lovaxin C vaccine being developed by Advaxis Inc. (OTC Bulletin Board: ADXS), is intended to treat cervical cancer and head and neck cancers that result from the human papilloma virus (HPV). This marked the first time the vaccine had been treated in humans.

"Our long held belief that live Listeria vaccines are safe, even in end stage cancer patients, has been confirmed with the results from our recent Phase I/II study. We have just entered the age of safe bacterial therapies," said Dr. John Rothman, VP of Clinical Development.

The immune response that Listeria generates is called "cellular" immunity, the type needed to attack cancer. Listeria is one of the strongest stimulators of cellular immunity known. "By redirecting it against specific tumor types safely, we have created a new, and potentially very effective, class of cancer therapy," says Rothman.

Advaxis reported treating fifteen patients in three dosage groups with thirty-minute 250 ml infusions of Lovaxin C at three-week intervals. Patients were observed for a total of 111 days. With the exception of two women, all patients had had either stage IVb advanced, recurrent, or progressive cervical cancer.

Every patient experienced a flu-like syndrome in the three-to-twelve hours after dosing comprised of fever, chills, nausea, and occasional vomiting, which is consistent with immune stimulation. In the lower two doses, symptoms were well tolerated and resolved with the use of over the counter analgesics and antihistamines.

Although efficacy was not a primary focus of the trial, efficacy findings were obtained. Of the seven stable patients, three had reductions in their tumor mass subsequent to treatment. While most lesions increased in size, tumor reduction was seen in a number of lesions an
'/>"/>

SOURCE Advaxis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... March 2, 2015 Isis Pharmaceuticals, Inc. (NASDAQ: ... $15 million milestone payment from GSK related to advancing the ... familial amyloid polyneuropathy (FAP).  "We are very ... , and plan to report data from the Phase 2/3 ... fifteen months of dosing and are now receiving ISIS-TTR Rx ...
(Date:3/2/2015)... BETHESDA, Md. , March 2, 2015 /PRNewswire/ ... treating and preventing autoimmune diseases, announced today that it ... 714) from Amgen (NASDAQ: AMGN ). Under ... the rights to develop, manufacture and commercialize AMG 714 ... . Concurrently, Amgen has been granted an exclusive option ...
(Date:3/2/2015)... Texas , March 2, 2015   Lexicon ... biopharmaceutical company focused on developing breakthrough treatments for human ... 2014 financial results on Wednesday, March 4, 2015 before ... conference call and webcast to discuss clinical development progress ... end of 2014 at 10:00 a.m. Eastern Time on ...
Breaking Medicine Technology:Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx 2Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx 3Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 2Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 3Lexicon To Report Fourth Quarter And Year End 2014 Financial Results On March 4, 2015 2
... Part D beneficiaries who enter the "donut hole," where ... prescription costs, are twice as likely to discontinue  their ... or generic medications, a new study published today in ... The study conducted by researchers from Harvard ...
... Aug. 16, 2011 BD (Becton, Dickinson and Company) ... technology company, today announced the completion of its acquisition ... the PhaSeal® System, the leading closed-system drug transfer device ... packaged in vials.  The acquisition expands the scope of ...
Cached Medicine Technology:CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 2CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 3BD Completes Acquisition of Carmel Pharma 2BD Completes Acquisition of Carmel Pharma 3
(Date:3/2/2015)... This year, the National Multiple Sclerosis Society’s annual awareness ... people across the country to unite, raise awareness, ... their best lives. MS Awareness Week is a special week ... the Society’s vision of a world free of MS. ... the central nervous system, interrupts the flow of information within ...
(Date:3/2/2015)... 02, 2015 Four Seasons Resort Maui at ... 25th anniversary this year, having officially opened its doors on ... resort is honoring over 70 employees who started on Day ... amongst the approximately 400 original employees. The celebration will ... Lawn. , This Four Seasons flagship resort, the ...
(Date:3/2/2015)... Houston, TX (PRWEB) March 02, 2015 ... CV? How should physicians request references? When are interviews ... physicians analyze employment opportunities?, Both training and practicing physicians ... answers to these questions and more at the PracticeLink ... March 18. The drop-in Job Fair is from 5:30 ...
(Date:3/2/2015)... Éminence Organic Skin Care, the leader ... to announce the launch of the Balance Collection, an ... solution for those with combination skin. The Balancing Masque ... jar to separate the products, consists of the Charcoal ... Moisturizer Duo, also in a divided jar, contains both ...
(Date:3/1/2015)... (PRWEB) March 02, 2015 Security ... the ancillary benefits market, announced the addition of ... PrimeStar Individual Vision Insurance launched today, complete with ... plan will utilize the VSP® Vision Care network ... the private practice space. The PrimeStar Select Vision ...
Breaking Medicine News(10 mins):Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:Celebrating Four Seasons Resort Maui’s 25th Anniversary 2Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2Health News:Éminence Organic Skin Care Launches Innovative Collection for Combination Skin 2Health News:Éminence Organic Skin Care Launches Innovative Collection for Combination Skin 3Health News:Security Life Insurance Company Launches Individual Vision Insurance Product 2
... ENT and ... “Holes in My Shoes.” The film made its broadcast premier last Holiday Season on ... at 10pm. , ... (Vocus) June 25, 2010 -- ENT and Allergy Associates, LLP (ENTA) is proud to ...
... ... in Certain Populations , ... Valencia, CA (PRWEB) June 25, 2010 -- The United States (U.S.) Centers for ... Mycobacterium tuberculosis infections, the causative agent of tuberculosis (TB). In these landmark guidelines, CDC ...
... Ross ... to Membership organizations that will help increase member retention, reduce cost and grow revenues. ... Atlanta, GA (PRWEB) ... MRM software and services to the American Automobile Association, announced today a strategic partnership ...
... Days ... the reports from northeastern Brazil where up to 100,000 people are feared to have lost ... Lakewood Ranch, ... towns “wiped off” the map. These are the reports from northeastern Brazil where up to ...
... York, June 25, 2010 Cardiac allograft vasculopathy (CAV), ... transplantation, occurs when blood vessels in a transplanted heart ... muscle or sudden death. Ascertaining benefit from appropriate treatment ... of the lack of a standard nomenclature. In an ...
... ... method that allows for significant risk reduction for index investing. Investors can ... limited or capped while reinvesting index gains accrued to lock in both ... of the principal value is invested and backed by FDIC insured bank ...
Cached Medicine News:Health News:ENT and Allergy Associates Sponsors Award Winning PBS Documentary 2Health News:TB Claims One Life Every 17 Seconds; Almost Two Million People Each Year 2Health News:TB Claims One Life Every 17 Seconds; Almost Two Million People Each Year 3Health News:Ross Group Inc Expands Offerings to Membership Clients 2Health News:Ross Group Inc Expands Offerings to Membership Clients 3Health News:ShelterBox Response Team Leaving for Flood Struck Brazil 2Health News:ShelterBox Response Team Leaving for Flood Struck Brazil 3Health News:New ISHLT cardiac allograft vasculopathy standardized nomenclature 2Health News:Principal Protected Index Investing Provides Innovative Method to Significantly Reduce Stock Market Loss and Risk 2Health News:Principal Protected Index Investing Provides Innovative Method to Significantly Reduce Stock Market Loss and Risk 3
Bougie Urethrotomes for slitting the female urethra and for meatus stenosis in males...
... Elite System™ and USA ... utilized for incision of ... neck contractures under direct ... converts the visual urethrotome ...
... Elite System™ and USA ... utilized for incision of ... neck contractures under direct ... converts the visual urethrotome ...
ACMI urethrotomes are available in two distinct styles to meet your specific professional needs. The Classic Series™ Otis Urethrotome consists of a blade, straight tip, and ball tip, with an av...
Medicine Products: